Why a Promising Cancer Immunotherapy Target Fails to Deliver in Animal Models

A common therapeutic target in cancer immunotherapy fails to deliver expected clinical benefits due to a massive biological sponge effect in the bloodstream. Researchers investigated why antibodies designed to block a specific lipid transporter on immune cells fall short of expectations, despite strong theoretical backing.

Why Certain Immune Cells Promote Tumor Growth

Tumor-associated macrophages, specialized immune cells that infiltrate tumor tissues, often adopt pro-tumorigenic behaviors that suppress immune responses and promote cancer progression. These suppressive cells frequently accumulate lipids and rely on specialized transport proteins to absorb oxidized fats from their environment. Scientists have long suspected that blocking these transport proteins could starve the suppressive cells and awaken the immune system to attack the cancer.

Researchers recently set out to discover and test new ways of reprogramming these immune cells through unbiased antibody screening techniques. Their findings were published in PLOS One, detailing a comprehensive evaluation of the multi-functional transmembrane receptor known as CD36. While laboratory experiments confirmed that high-affinity monoclonal antibodies could successfully block lipid uptake in engineered cell lines, the strategy hit a major roadblock when tested on primary human cells and living animal models.

The Unexpected Obstacle of Bloodstream Binding

The primary reason for the treatment failure lies in a pharmacological phenomenon known as target-mediated drug disposition. CD36 is not only found on immune cells within tumors, but it is also abundantly expressed on healthy red blood cells, platelets, and endothelial cells lining blood vessels. When researchers administered anti-CD36 antibodies to mice, the circulating red blood cells acted as a massive antigen sink, soaking up nearly all the free antibody before it could ever reach the tumor microenvironment.

Measurements of free plasma concentrations showed that standard doses of the antibody became virtually undetectable within minutes of injection. Even when researchers increased the dosing frequency and pushed concentrations to high levels, target occupancy on tumor-infiltrating myeloid cells reached only about 30 percent. This severe lack of bioavailability prevented the therapy from exerting any meaningful anti-tumor effects across multiple aggressive cancer models, including melanoma and fibrosarcoma.

Redundant Pathways and Cellular Complexity

Beyond the problem of delivery, experiments on primary human macrophages revealed a deeper biological hurdle involving pathway redundancy. Unlike simple engineered cell lines, primary macrophages possess a wide array of alternative scavenger receptors and lipid transporters that can compensate when CD36 is blocked. When CD36 was inhibited by antibodies, the macrophages simply relied on other molecular pathways to take up oxidized lipids, leaving their suppressive behavior unchanged.

The authors caution that while genetic knockout models and chemical inhibitors have previously suggested that eliminating CD36 can curb tumor growth, traditional monoclonal antibody approaches face severe structural and biological barriers. Overcoming these hurdles will likely require advanced protein engineering, such as bispecific designs that minimize off-target binding in the circulation, much like strategies currently being developed to improve other challenging immune-oncology therapies.

The research was published in PLOS One on November 12, 2026.